The Cell Therapy Market Is Expected To Grow 600% By 2033. This Biotech Is Poised To Capitalize.

Over the last decade, cell therapies have attracted a lot of investor attention to biotechs. These groundbreaking treatments use a patient’s own cells to create personalized medicine that not only improves wellness outcomes for people, but it has the ability to transform the health care and pharmaceutical industries.

On this Growth Stories Spotlight, we talk to Vericel CEO Nick Colangelo to get his insights on the cell therapy market, his plans to expand MACI and burn care treatments and why he thinks Vericel has a unique position in the competitive landscape.

New to trading? Check out our daily newsletter! https://get.investors.com/marketdiem/

Get more IBD by subscribing to our channel:    / @investorsbusinessdaily  

Visit our website: https://www.investors.com
Like us on Facebook:   / investorsbusinessdaily  
Follow us on Twitter:   / ibdinvestors  
Follow us on Instagram:   / investorsbusinessdaily  
Follow us on StockTwits: https://stocktwits.com/InvestorsBusin...
Follow us on LinkedIn:   / investors-business-daily  
Follow us on TikTok:   / ibdinvestors  

Investor’s Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing data, stock market research, education and the latest financial and business news to help investors make more money in the stock market.

#InvestorsBusinessDaily #IBD